A generic version of Inlyta (axitinib) is not available at this time, as this drug is protected by patents that prevent a company from making a generic Inlyta product. However, the first patent is expected to expire in January 2020. After this patent expires, a generic version of the drug may become available, unless lawsuits, new patents, or other circumstances prevent this from happening.
Can I Buy Generic Inlyta?Inlyta® (axitinib) is a prescription medication approved for the treatment of kidney cancer. It is used in people who have not adequately responded to at least one other kidney cancer medication.
Inlyta is made by Pfizer, Inc. It is protected by patents that prevent any generic Inlyta from being manufactured in the United States.
When Will a Generic Version Be Available?The first patent for Inlyta is set to expire in January 2020. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten the exclusivity period. This could include such things as lawsuits or patents for new Inlyta uses. Once Inlyta goes off-patent, there may be several companies that manufacture a generic Inlyta drug.
Is Axitinib a Generic Inlyta?No -- axitinib is the active ingredient in Inlyta, but it is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.